GSK announces plans to increase transparency of clinical research
Pharma Compliance Alert, April 1, 2009
GlaxoSmithKline (GSK) will disclose payments to U.S. healthcare professionals and their institutions to conduct clinical trials beginning in 2010, according to the company’s 2008 Corporate Responsibility Report.
In the future, GSK plans to disclose payments for other types of research and to healthcare professionals and institutions outside the United States. The company also plans to expand publication of clinical trials on its Clinical Study Register to include all meta-analyses, observational studies, and studies of terminated compounds.
Read more about GSK’s plans to increase transparency.
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- Case Management Monthly, March 2012
- Searched
